

future science group

# Catalogue

2013



[www.future-science-group.com](http://www.future-science-group.com)



## What are you looking for?

### The Expert Review Series 4–25

“Your essential medical review collection”

18 journals covering all aspects of modern medicine.

---

### Future Medicine Journals 26–58

“Tomorrow’s medicine today”

29 journals providing cutting-edge coverage of postgenomic medicine.

---

### Future Science Journals 60–70

“Revelations in R&D”

High-quality commentary and analysis in today’s key areas of research endeavor.

### Subject collections 71–75

“Your Complete Digital Library”

To help you pinpoint the most relevant titles for you, we have highlighted journals that fall within one of our subject collections: Oncology, Cardiology, Immunology, Neurology and Environmental. Look for the subject collection tab on each journal page.



### Our eBooks 76–77

“Your essential resources for scientific research”

Over 100 eBooks written by some of the world’s leading experts covering the most important and emerging areas in medicine today.

# Contents

## Full contents

### The Expert Review Series

Expert Review of Anticancer Therapy	8	Future Neurology	41
Expert Review of Anti-infective Therapy	9	Future Oncology	42
Expert Review of Cardiovascular Therapy	10	Future Virology	43
Expert Review of Clinical Immunology	11	Imaging in Medicine	44
Expert Review of Clinical Pharmacology	12	Immunotherapy	45
Expert Review of Dermatology	13	International Journal of Hematologic Oncology	46
Expert Review of Endocrinology & Metabolism	14	International Journal of Clinical Rheumatology	47
Expert Review of Gastroenterology & Hepatology	15	Interventional Cardiology	48
Expert Review of Hematology	16	Journal of Comparative Effectiveness Research	49
Expert Review of Medical Devices	17	Lung Cancer Management	50
Expert Review of Molecular Diagnostics	18	Nanomedicine	51
Expert Review of Neurotherapeutics	19	Neurodegenerative Disease Management	52
Expert Review of Obstetrics & Gynecology	20	Neuropsychiatry	53
Expert Review of Ophthalmology	21	Pain Management	54
Expert Review of Pharmacoeconomics & Outcomes Research	22	Personalized Medicine	55
Expert Review of Proteomics	23	Pharmacogenomics	56
Expert Review of Respiratory Medicine	24	Regenerative Medicine	57
Expert Review of Vaccines	25	Women's Health	58
<b>Future Medicine Journals</b>		<b>Future Science Journals</b>	
Aging Health	30	Bioanalysis	63
Biomarkers in Medicine	31	Biofuels	64
Breast Cancer Management	32	Carbon Management	65
Clinical Lipidology	33	Clinical Investigation	66
Clinical Practice	34	Future Medicinal Chemistry	67
CNS Oncology	35	Pharmaceutical Bioprocessing	68
Colorectal Cancer	36	Pharmaceutical Patent Analyst	69
Diabetes Management	37	Therapeutic Delivery	70
Epigenomics	38	Subject collections	71
Future Cardiology	39	Ebooks	76
Future Microbiology	40	Publication solutions	78
		Information for librarians	80
		Information for authors	82



## Welcome to the Future Science Group 2013 catalogue

The Future Science Group is an alliance of three independent publishing companies – Expert Reviews, Future Medicine and Future Science – focusing on new findings and critical commentary at the cutting edge of modern science. This year we'd like to draw your attention, in particular, to our expanding oncology program, a further commitment to our R&D coverage and development of our eBooks in clinical practice and biomedicine.



### Extensive Oncology Coverage

We are pleased to announce a significant increase in our oncology coverage within Future Medicine with a suite of key specialty titles from 2012 through 2013 that are available individually or as a collection:

- *Breast Cancer Management*
- *Colorectal Cancer*
- *CNS Oncology*
- *International Journal of Hematologic Oncology*
- *Lung Cancer Management*

These new peer-reviewed specialty titles augment the established titles providing coverage of new findings and concise readable clinical overviews in key areas of cancer diagnosis and management.




### Focus on R&D

We also have added to the coverage of applied pharmaceutical sciences with the launch of *Pharmaceutical Bioprocessing* from Future Science. This builds on the established pharma R&D coverage of titles such as *Bioanalysis*, *Future Medicinal Chemistry* and *Pharmaceutical Patent Analyst*. The journal serves as an authoritative forum for insights into the latest advances in the design and development of production systems and processes for the generation of pharmaceutical products. Coverage encompasses the full scope of pharmaceutical production, including vaccines, biologics and regenerative medicine therapies.


# Welcome

## Expanding eBook Programs



2013 sees the launch of the 'Ask the Experts' eBook series from **Expert Reviews**. With a highly practical didactic format addressing key issues in modern clinical practice, this collection is set to be a real asset for practising clinicians.

**Future Medicine's** new eBook series program, launched in 2012, is expanding further to provide students, researchers and clinicians with access to an online collection of key biomedical titles. Designed to deliver insightful, concise commentary from international opinion leaders, our titles address key topics and breakthroughs in modern medicine, including the oncology, immunology, neurology, cardiology and infectious disease subject areas.



Best wishes for 2013,

The Future Science Group team



# The Expert Review Series

Critical analysis in modern medicine

The Expert Reviews series of journals delivers systematic, authoritative analysis and insightful commentary from international experts

18 titles covering all aspects of modern medicine

Institutional trials available – visit our website to find out more

[www.expert-reviews.com](http://www.expert-reviews.com)

EXPERT  
REVIEWS



# The essential medical review collection

## Benefits of the Expert Review series

**Highly structured format:** Each review provides a complete overview of current thinking on a specific topic of research. This is augmented by a specially structured format that maximizes accessibility.

**Timely reviews:** The Expert Reviews series features timely articles published monthly or bi-monthly by leading experts in the field. This series of journals covers a broad range of scientific fields to ensure that your team is kept up-to-date on the latest advances and techniques in healthcare and clinical practice, whatever your discipline.

**High-quality imagery and tabular data:** To maximise readability and accessibility, the Expert Reviews journals are produced to the highest production standards featuring our award-winning design, professional layout, high-quality images and graphically enhanced tabular data.

**Acclaimed authors and editorial boards:** The Expert Reviews series is a leading forum for discussion on clinical medicine – expert advisory panels identify leading authors and hot topics. Through the publication of timely Reviews, News, Interviews and Special Reports, these journals are the gateway to cutting-edge discussion and debate in the field.

**Rigorous peer review and a dedicated in-house editorial team:** A dedicated in-house editorial team ensures that these journals publish the most relevant topics in contemporary clinical medicine all within industry-leading time frames. Each article commissioned is subject to rigorous peer review by three independent experts, to ensure quality and accuracy of content.

# The Essential Medical Review Collection

Expert Reviews  
Journal Collection

18 titles  
covering all aspects  
of modern medicine



Institutional trials available  
Visit our website to find out more

[www.expert-reviews.com](http://www.expert-reviews.com)

EXPERT  
REVIEWS





# Contents

Expert Review of Anticancer Therapy	8
Expert Review of Anti-infective Therapy	9
Expert Review of Cardiovascular Therapy	10
Expert Review of Clinical Immunology	11
Expert Review of Clinical Pharmacology	12
Expert Review of Dermatology	13
Expert Review of Endocrinology & Metabolism	14
Expert Review of Gastroenterology & Hepatology	15
Expert Review of Hematology	16
Expert Review of Medical Devices	17
Expert Review of Molecular Diagnostics	18
Expert Review of Neurotherapeutics	19
Expert Review of Obstetrics & Gynecology	20
Expert Review of Ophthalmology	21
Expert Review of Pharmacoeconomics & Outcomes Research	22
Expert Review of Proteomics	23
Expert Review of Respiratory Medicine	24
Expert Review of Vaccines	25


# Expert Review of Anticancer Therapy

ISSN: 1473-7140

Volume: Number 13 (2013)

Frequency: 12 issues per year

Impact Factor: 2.652 (2011)



*Expert Review of Anticancer Therapy* provides informed analysis and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic modalities. Each monthly issue, themed towards specific tumor sites, contains a selection of articles covering the key topics ranging from novel medicines and anticancer agents to tumor management and treatment guidelines. The journal's audience includes oncologists, hematologists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Expert Review of Anticancer Therapy has been a high-quality journal from the outset. I look forward to the journal continuing to stimulate novel debate in the field of cancer in years to come.”*

**Hitendra RH Patel**, University Hospital of North Norway, Norway

## Coverage includes:

- Therapeutic overviews of specific cancers and emerging therapeutic indications
- Performance and benefits of newly approved anticancer agents
- Prospects for medicines in late-stage trials approaching regulatory approval
- Epidemiologic studies highlighting prospects for cancer prevention and control
- New diagnostic approaches to screening and patient stratification

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, Scopus®



# Expert Review of Anti-infective Therapy

ISSN: 1478-7210

Volume: Number 11 (2013)

Frequency: 12 issues per year

Impact Factor: 3.283 (2011)



*Expert Review of Anti-infective Therapy* provides critical analysis and commentary on the latest approaches to the management of bacterial, viral, fungal and parasitic infectious diseases and the development of new anti-infective therapies. Updates are provided on the emergence of antimicrobial resistance and methods to tackle this increasingly serious threat. The review content of the journal is supplemented with cutting-edge editorial articles covering the latest outbreaks of infectious disease and the most up-to-date methods of managing these dynamic conditions. The journal's audience includes clinicians specialising in infectious diseases, microbiologists, bacteriologists, immunologists, mycologists, parasitologists, virologists, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Expert Review of Anti-infective therapy develops current topics in the field of infectious diseases, emphasizes emerging trends and discusses future therapeutic strategies.”*

**Marie-Thérèse Labro**, INSERM, France

## Coverage includes:

- Understanding infectious diseases
- New and emerging therapeutic approaches
- Diagnostic technologies
- Antimicrobial resistance
- Increasing prevalence of viral infections

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Scopus®




# Expert Review of Cardiovascular Therapy

ISSN: 1477-9072

Volume: Number 11 (2013)

Frequency: 12 issues per year



Cardiovascular disease constitutes the largest cause of death throughout the world. *Expert Review of Cardiovascular Therapy* provides an accessible forum for the discussion and evaluation of new therapeutic and diagnostic modalities that aim to reduce this burden. Within this well-established journal, topics such as heart disease, vascular disorders, hypertension, stroke, heart failure and cardiovascular surgery are examined, with expert authors providing a comprehensive update on current practice in key clinical areas. Each monthly issue focuses on specific key topics. The journal's audience includes cardiologists, lipidologists, hematologists, clinicians, research clinicians, academic and pharmaceutical scientists, general practitioners, policy and decision makers, epidemiologists, healthcare professionals and regulatory personnel.

*“Expert Review of Cardiovascular Therapy is an extremely useful guide for clinicians that provides in-depth and timely overviews on all aspects of cardiovascular treatment. World-renowned experts contribute the latest knowledge in the field of cardiovascular medicine combined with their invaluable perspective, thereby opening new horizons in clinical and basic research.”*

**Yiannis S Chatzizisis**, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA

## Coverage includes:

- Performance and benefits of newly approved cardiovascular therapeutic agents
- Prospects for new therapies
- Epidemiologic studies and trends
- New diagnostic approaches, screening and patient stratification
- Pharmacoeconomics and outcomes research

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, Chemical Abstracts, CINAHL® Plus, Scopus®



# Expert Review of Clinical Immunology

ISSN: 1744-666X

Volume: Number 9 (2013)

Frequency: 12 issues per year

Impact Factor: 2.072 (2011)



## Senior Editors

**Thomas Forsthuber**, University of Texas at San Antonio, USA

**Timothy Radstake**, University Medical Center Utrecht & Wilhelmina Children's Hospital, Utrecht, The Netherlands

*Expert Review of Clinical Immunology* provides a centralized resource of commentary and debate on a rapidly developing field, helping to inform clinical and economic decision-making in healthcare for immunologic disorders. In addition to strengthening the bridge between basic and clinical research, international experts outline current best practice for diagnosis and therapy and provide their leading opinion on the future development of these tools for autoimmune, allergic, inflammatory and other immune-mediated disorders in the next 5 years. The journal's audience includes clinical immunologists, researchers in immunology, general practitioners, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Expert Review of Clinical Immunology brings up-to-date information in the field of allergy and clinical immunology vitally needed by the busy clinician. It is a 'must read' for anyone interested in this ever-changing specialty of medicine."*

**Michael Blaiss**, University of Tennessee Health Science Center, TN, USA

## Coverage includes:

- New diagnostic approaches
- Therapeutic overviews and new therapeutic indications for specific immunologic disorders
- Immunopathophysiology and implications for treatment
- Performance and benefits of newly approved therapeutic agents
- Prospects for medicines in late-stage trials approaching regulatory approval

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Scopus®



# Expert Review of Clinical Pharmacology

ISSN: 1751-2433

Volume: Number 6 (2013)

Frequency: 6 issues per year



## Senior Editors

**Ken Kaitin**, Tufts Center for the Study of Drug Development, MA, USA

**Maarten Postma**, University of Groningen, The Netherlands

**Joe Blondeau**, University of Saskatchewan, Canada

*Expert Review of Clinical Pharmacology* bridges the gap between the medical profession, clinical research and the pharmaceutical industry, providing researchers, specialists, physicians and other healthcare professionals with the key information they need to facilitate progress in pharmacological therapy. The journal provides a forum for informed debate and critical analysis of all aspects of safety, tolerability, efficacy and therapeutic applications, in addition to covering toxicity issues, adverse reactions, pharmacoeconomics and societal issues. The journal's audience includes pharmacologists, toxicologists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"The journal is at the intersection of science and clinical medicine, providing a synthesis of bench-to-bedside translation."*

**Scott A Waldman**, Thomas Jefferson University, USA

## Coverage includes:

- ADME studies and PK/PD modelling
- Adverse effects/reactions, drug–drug and drug–disease interactions, toxicology
- Pharmacogenetics, genomics, the incorporation of new biomarkers in drug development and clinical practice
- Pharmacoepidemiology, risk management and pharmacovigilance
- Regulation of drug development and marketing; novel clinical trial design and conduct

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®

# Expert Review of Dermatology

ISSN: 1746-9872

Volume: Number 8 (2013)

Frequency: 6 issues per year



*Expert Review of Dermatology* provides rapid publication of commentary and analysis on the latest research and clinical advances in all areas of dermatology. In collaboration with an expert editorial board, our dedicated editorial team commission state-of-the-art updates on the challenges for the specialty in a new medical era. The journal's audience includes dermatologists, general practitioners, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Expert Review of Dermatology is an important resource for dermatologists and a valuable reference for anyone interested in dermatologic disease. The reviews are comprehensive, timely and accurate.”*

**Mark Lebwohl**, Mount Sinai Medical Center, NY, USA

## Coverage includes:

- Updates on novel diagnostic techniques and preventive strategies
- Evaluation of performance and comparison of existing and novel therapeutic indications
- Discussion of ethical considerations for clinical and experimental research
- New understanding of dermatologic disease processes
- Hot topics in current dermatology practice including: melanoma diagnostics, teledermatology and novel therapies of atopic dermatitis

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®

# Expert Review of Endocrinology & Metabolism

ISSN: 1744-6651

Volume: Number 8 (2013)

Frequency: 6 issues per year



## Editor-in-chief

**Kjell Oberg**, Uppsala University, Sweden

*Expert Review of Endocrinology and Metabolism* provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a particular focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology. This resource encompasses the most stimulating and up-to-date topics in areas such as diabetes, osteoporosis, thyroid disease, adrenal insufficiency and pituitary tumors, as well as disorders associated with growth, reproduction, weight management and hormone-regulated gene expression. The journal's audience includes specialists in metabolic disorders, endocrinologists, diabeticians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Expert Review of Endocrinology and Metabolism is an advancing medical journal which provides continuously high-quality reports."*

**Maria Brandi**, University of Florence, Italy

## Coverage includes:

- Updates on the impact of clinical and epidemiology studies in the field
- Discussion on the clinical diagnosis and management of common and rare endocrine and metabolic diseases
- Screening and prevention
- Drug profiles on key drugs in the field as they are approved
- Reviews on current hot topics such as male hormonal contraception, bone metabolism and control of obesity

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®




# Expert Review of Gastroenterology & Hepatology

ISSN: 1747-4124

Volume: Number 7 (2013)

Frequency: 8 issues per year



*Expert Review of Gastroenterology & Hepatology* provides systematic, authoritative analysis on the understanding, diagnosis, treatment and prevention of gastrointestinal and liver disease. Aiming to serve a wide range of professionals within the field, the resource includes updates on interventional and therapeutic advances in cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption and secretion. *Expert Review of Gastroenterology & Hepatology* provides peer-reviewed expert commentary on the most stimulating and up-to-date topics, making it an essential resource for clinicians and researchers alike. The journal's audience includes gastroenterologists, hepatologists, abdominal surgeons, clinicians, general practitioners, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Five-star reviews – informative, up-to-date and thorough, from key opinion leaders."*

Derek Jewell, University of Oxford, UK

## Coverage includes:

- Latest advances in our understanding of disease
- Medical, radiological, pathological, biochemical and physiological aspects
- Advances in diagnostic technologies
- Performance and benefits of new and existing drug treatments
- Pharmacoeconomics and outcomes research

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports®, Chemical Abstracts, Scopus®


# Expert Review of Hematology

**ISSN:** 1747-4086

**Volume:** Number 6 (2013)

**Frequency:** 6 issues per year

**Impact Factor:** 1.161 (2011)



Advanced molecular research techniques have transformed hematology in recent years. *Expert Review of Hematology* aims to put these advances into clinical context and explores how they will translate into practice. Focusing on the research and evaluation of new drugs and treatment approaches, novel diagnostic techniques and advances in knowledge, this cutting-edge resource assists hematologists in defining best possible patient care. The journal's audience includes hematologists, cardiologists, oncologists, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Expert Review of Hematology offers a perspective that differs greatly from other journals. Articles are broad, peer reviewed and add a great deal to the armamentarium of a treating physician."*

**Lou Aledort**, Mount Sinai School of Medicine, NY, USA

#### Coverage includes:

- Leukemias and lymphomas
- Bone marrow and hematopoietic stem cell transplantation
- Immunodeficiency syndromes and marrow failure syndromes
- Multiple myeloma, amyloidosis and myeloproliferative disorders
- Hemoglobinopathies and transfusion medicine

#### Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Scopus®



# Expert Review of Medical Devices

ISSN: 1743-4440

Volume: Number 10 (2013)

Frequency: 6 issues per year

Impact Factor: 2.632 (2011)



Research and development in the medical device arena is multidisciplinary in nature; exciting advances are enabling increasingly more precise clinical interventions and a fascinating integration of different approaches and technologies is taking place. *Expert Review of Medical Devices* focuses on new and emerging therapies, device performance in a range of clinical settings, biocompatibility issues, biomedical materials, tissue engineering and drug-delivery devices, and provides a single forum for commentary, analysis and debate for all professionals involved in research, development, testing and clinical use of devices. The journal's audience includes clinicians with specialized interests in device technologies and applications, cardiologists, diabetologists, pharmaceutical scientists, biomedical engineers, specialists in medical physics, materials scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Expert Review of Medical Devices enables an inside look into a broad field of devices interacting with the human body. Experts are focusing on state-of-the-art, current challenges and future perspectives from both directions, of a researcher and of a clinician."*

**Leonid Goubergrits**, Humboldt University of Berlin, Germany

## Coverage includes:

- Implants and prostheses
- Biomedical materials: mechanical, physical, chemical and biological properties
- Nanotechnology in device development
- Medical imaging and nuclear medicine
- Drug-delivery devices and device/drug hybrid products

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Current Contents®/Engineering Computing and Technology, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, Compendex, Scopus®

# Expert Review of Molecular Diagnostics

ISSN: 1473-7159

Volume: Number 13 (2013)

Frequency: 8 issues per year

Impact Factor: 4.859 (2011)



## Associate Editors

**William CS Cho**, Queen Elizabeth Hospital, Hong Kong; **Samir Hanash**, Fred Hutchinson Cancer Research Center, USA; **Tim Harris**, SAIC-Frederick Inc., USA; **George Poste**, Arizona State University, USA; **Dimitris Roukos**, Ioannina University, Greece; **Jeffrey S Ross**, Albany Medical College, USA

It is an exciting time for the field of molecular diagnostics, with rapid growth and development in next-generation sequencing and the application of biomarker and epigenetic research to clinical diagnostics. *Expert Review of Molecular Diagnostics* publishes leading analysis of the latest advancements in the field, including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking technologies to be used in the clinical diagnostic setting. *Expert Review of Molecular Diagnostics* provides authoritative and expert commentary on a wide range of topics, making it an essential resource for clinicians and researchers alike. The journal's audience includes physicians and practicing scientists in molecular diagnostics, pathologists, clinical laboratory researchers and specialists in clinical genetics, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"The field of molecular diagnostics is moving very rapidly and Expert Review of Molecular Diagnostics is an excellent resource to stay up-to-date on developments in the field."*

**Samir Hanash**, Fred Hutchinson Cancer Research Center, USA

## Coverage includes:

- Application of technological advances in molecular diagnostic medicine
- Emerging 'omic' diagnostic technologies including: pharmacogenomic, epigenomic, proteomic and metabolomic technologies
- Disease predisposition and inherited genetic disease testing and monitoring
- Development and improvement of current molecular diagnostic tests
- Tracking of drug–diagnostic co-developments

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (Web of Science), Current Contents®/Clinical Medicine, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®

# Expert Review of Neurotherapeutics

ISSN: 1473-7175

Volume: Number 13 (2013)

Frequency: 12 issues per year



*Expert Review of Neurotherapeutics* provides a comprehensive coverage of emerging strategies and therapeutic modalities in clinical neurology and neuropsychiatry. Published in monthly themed issues, *Expert Review of Neurotherapeutics* comprises focused state-of-the-art updates on disease management, diagnostics and treatment guidelines for conditions such as stroke, epilepsy, Alzheimer's and Parkinson's disease. High-quality peer-reviewed content delivered by industry-leading experts is presented in an at-a-glance format to assist busy professions in clinical decision-making and best possible patient care. The journal's audience includes neurologists, neurosurgeons, psychiatrists, pharmacologists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Expert Review of Neurotherapeutics is a unique journal dealing with disorders of the nervous system that provides clinicians with comprehensive summaries of important clinical issues to assist in their decision-making."*

**Jay S Schneider**, Thomas Jefferson University, USA

## Coverage includes:

- Therapeutic overviews of specific disease areas, highlighting optimal therapy
- Latest advances in our understanding of emerging treatment options
- New diagnostic approaches, screening and patient stratification
- Performance and benefits of newly approved neurotherapeutic agents
- Disease and treatment issues for defined populations

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Neuroscience Citation Index®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, PsycINFO, Scopus®




# Expert Review of Obstetrics & Gynecology

ISSN: 1747-4108

Volume: Number 8 (2013)

Frequency: 6 issues per year



*Expert Review of Obstetrics & Gynecology* provides evaluated, structured commentary from international opinion leaders in this key field of medical endeavour. The varied coverage of the journal includes advances in diagnostic approaches, prenatal diagnosis, contraception, fertility and conception, as well as gynecologic oncology and pathology. Reviews are subject to rigorous peer review and produced to industry-leading standards and timelines to ensure a complete solution for professionals working in the dynamic and fast-moving field of obstetric and gynecological research. The journal's audience includes obstetricians, gynecologists, clinicians, general practitioners, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Expert Review of Obstetrics & Gynecology is a journal to help explore advanced knowledge, find latest medical practices and the direction for tomorrow’s possibilities.”*

**Kristina Gemzell-Danielsson**, Karolinska Institutet, Sweden

## Coverage includes:

- Advances in diagnostic approaches, prenatal diagnosis
- Fertility and conception
- Contraception: benefits and adverse effects of novel and existing strategies
- Maternal–fetal medicine
- Gynecologic oncology and pathology

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®

# Expert Review of Ophthalmology

ISSN: 1746-9899

Volume: Number 8 (2013)

Frequency: 6 issues per year



*Expert Review of Ophthalmology* provides an important platform and fresh approach for commentary in this globally significant area, including debate on current and emerging approaches in ocular medicine. As longevity increases worldwide, visual impairment problems are also set to increase. With the majority of vision loss treatable or preventable, the prospects for ophthalmic intervention are constantly being pushed to new boundaries. This exciting resource provides the ophthalmology community with access to a wealth of high-quality, peer reviewed information from the leading experts in the field. *Expert Review of Ophthalmology* aims to distil the clinical significance of novel developments to provide an at-a-glance update for the busy ophthalmologist. The journal's audience includes ophthalmologists, clinicians, general practitioners, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Expert Review of Ophthalmology provides the practical clinician with a concentration of science and the most relevant peer-reviewed information on specific topics relevant for practice. It creates a bridge between newly generated information, the clinicians using procedures and experienced authors. An extremely useful tool on the desk of the modern ophthalmologist."*

**Jorge Alió**, Visum Instituto de Oftalmologico de Alicante, Spain

## Coverage includes:

- Therapeutic approaches in ophthalmic disorders
- Ocular tumors
- Surgical techniques and new instruments
- Molecular biology and molecular genetics in ophthalmology
- Management of ocular infections and inflammation

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®

# Expert Review of Pharmacoeconomics & Outcomes Research

ISSN: 1473-7167

Volume: Number 13 (2013)

Frequency: 6 issues per year



## Senior Editor

**Andrew Bottomley**, EORTC, Belgium

Society is experiencing major shifts in demographics, technology and economics, and these changes are creating dilemmas for a range of stakeholders – including the pharmaceutical industry, healthcare organizations, governments and patients. At the same time, advances in science are resulting in the proliferation of new medicines. Whilst the technological advances are hugely exciting, the reality is that the costs of drug development are spiraling. *Expert Review of Pharmacoeconomics & Outcomes Research* provides commentary and analysis on the relationship between economic factors and clinical prescribing decisions, providing a practical background to informed prescribing decisions and allocation of healthcare resources. The journal's audience includes health economists, outcomes researchers, policy and decision makers, healthcare professionals, regulatory personnel, academic and pharmaceutical scientists, clinicians and general practitioners.

*“What makes the reviews in Expert Review of Pharmacoeconomics & Outcomes Research unique is the inclusion of the author’s personal perspective on where the field is going in the future. This provides valuable insights that go well beyond the discussion sections of most journals.”*

**Carolyn Gotay**, University of British Columbia, Canada

## Coverage includes:

- Reviews of pharmacoeconomic and quality-of-life literature
- Overviews of outcomes findings in specific therapeutic areas and disease states
- Decision-making tools
- Drug utilization review and evaluation
- Healthcare policy

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, CINAHL®Plus, Scopus®, Science Citation Index Expanded™ (SciSearch®), Social Sciences Citation Index, Current Contents®/Social and Behavioral Sciences, Current Contents®/Clinical Medicine




# Expert Review of Proteomics

**ISSN:** 1478-9450

**Volume:** Number 10 (2013)

**Frequency:** 6 issues per year

**Impact Factor:** 3.685 (2011)



*Expert Review of Proteomics* collects together technologies, methods and discoveries from the field of proteomics to advance scientific understanding of the many varied roles protein expression plays in human health and disease. The journal covers a broad range of articles, including reviews of recently released proteome sequencing data to coverage of the latest diagnostic techniques. The journal's audience includes clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Expert Review of Proteomics is one of my key sources for the latest updates on what is novel in the field of proteomics. I enjoy reading the editorials as they are always insightful and not shy about pointing out what is lacking in proteomics research."*

**Timothy Veenstra**, National Cancer Institute, USA

## Coverage includes:

- Development of protein arrays
- Biological assays
- Metabolomics
- Protein biomarker discovery
- Mass spectrometry technology

## Indexing:


MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (Web of Science), Biochemistry & Biophysics Citation Index™, Journal Citation Reports/Science Edition®

# Expert Review of Respiratory Medicine

ISSN: 1747-6348

Volume: Number 7 (2013)

Frequency: 6 issues per year



Respiratory disease imposes a global burden affecting hundreds of millions worldwide. *Expert Review of Respiratory Medicine* aims to assist clinicians and researchers in meeting the challenge of staying abreast of the latest developments in the field. With peer-reviewed and structured commentary from international leaders in the fields, *Expert Review of Respiratory Medicine* provides a comprehensive update on obstructive, restrictive, vascular and infectious respiratory diseases for those involved in all areas of pulmonary medicine. The journal's audience includes clinicians in respiratory medicine, pulmonologists, internists, cardiologists, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Expert Review of Respiratory Medicine is an educational tool for both training and expert scientists and practitioners in medicine by means of reviews and state-of-the-art articles in all fields of respiratory medicine.”*

**Nicolino Ambrosino**, University Hospital Pisa, Italy

#### Coverage includes:

- Improved diagnostic methods, including imaging techniques and biomarkers
- Advances in the treatment of respiratory infections and drug resistance issues
- Disease and treatment issues for defined populations, such as children and the elderly
- Respiratory intensive and critical care
- Updates on the status of and advances in specific disease areas

#### Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®



Your essential  
resources  
in print and online

# Future Medicine

“Tomorrow’s medicine today”

Future Medicine provides cutting-edge coverage of postgenomic medicine. Our publications provide healthcare practitioners and research professionals with a unique source of original research and topical reviews

[www.futuremedicine.com](http://www.futuremedicine.com)

Future  
Medicine 

## Benefits of the Future Medicine series

**Timely reviews and high-quality original research:** This series of journals covers a broad range of scientific fields to ensure that your team is kept up-to-date on the latest advances and techniques in healthcare and clinical practice, whatever your discipline.

**Highly structured format:** Each article provides a complete overview of current thinking on that topic of research. This is augmented by a specially structured format.

**High-quality imagery and tabular data:** Produced to the highest production standards and featuring our award-winning design, professional layout, high-quality images and graphically enhanced tabular data.

**Acclaimed authors and editorial boards:** Future Medicine journals are leading forums for discussion on all aspects of medicine and we work closely with our Senior Editors and expert advisory panels to identify leading authors and hot topics.

**Rigorous peer review and a dedicated in-house editorial team:** Dedicated in-house editorial team ensures that our journals publish the most relevant topics in contemporary medicine, all within industry-leading time frames. Each article commissioned is subject to rigorous peer review by three independent experts, to ensure quality and accuracy at all times.

**High visibility:** Our journals are indexed on many of the leading abstracting services including ISI Science Citation Index, MEDLINE, EMBASE and Chemical Abstracts. See individual journals for full details.

**Rapid publication:** We offer rapid publication as standard, ensuring the most up-to-date information is processed expeditiously.



# Contents

Aging Health	30	International Journal of Hematologic Oncology	46
Biomarkers in Medicine	31	International Journal of Clinical Rheumatology	47
Breast Cancer Management	32	Interventional Cardiology	48
Clinical Lipidology	33	Journal of Comparative Effectiveness Research	49
Clinical Practice	34	Lung Cancer Management	50
CNS Oncology	35	Nanomedicine	51
Colorectal Cancer	36	Neurodegenerative Disease Management	52
Diabetes Management	37	Neuropsychiatry	53
Epigenomics	38	Pain Management	54
Future Cardiology	39	Personalized Medicine	55
Future Microbiology	40	Pharmacogenomics	56
Future Neurology	41	Regenerative Medicine	57
Future Oncology	42	Women's Health	58
Future Virology	43		
Imaging in Medicine	44		
Immunotherapy	45		

# Aging Health

ISSN: 1745-509X

Volume: Number 9 (2013)

Frequency: 6 issues per year



*Aging Health* reviews the prevention, diagnosis, treatment and management of diseases and medical conditions important to the elderly today. As the mechanisms underlying disease and disability in the elderly become better understood, there is an increasing requirement for a centralized forum for commentary and analysis of the rapidly expanding wealth of information in this field. *Aging Health* focuses on the most important advances and highlights their relevance in the clinical setting. The journal's audience includes neurologists, gerontologists, cardiologists, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"In spite of the increasing older population, the field of geriatrics is still not yet widespread throughout the world, even in well-developed countries the geriatric culture is present only in some regions or cities. Aging Health is helping to fill this gap."*

**Silvio Monfardini**, Istituto Palazzolo, Milan, Italy

## Coverage includes:

- Current and emerging topics relating to the safe and effective management of therapy in the older patient
- Hot topics in neurodegenerative disease, and areas of fast-evolving research of particular importance to elderly patients
- Bone health and rheumatology, a top priority for many older patients
- An in-depth the look at the emerging field of geriatric oncology and what specialised cancer treatment means for the older patient
- Appropriate care of older patients and what we can do to improve quality of life in the older population

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®, Age Info



# Biomarkers in Medicine

ISSN: 1752-0363

Volume: Number 7 (2013)

Frequency: 6 issues per year

Impact Factor: 2.63 (2011)



## Senior Editors

**Andre Terzic**, Professor of Medicine, Mayo Clinic College of Medicine, USA

**Scott A Waldman**, Samuel MV Hamilton Professor & Director, Thomas Jefferson University, USA

The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in medical practice, as well as in the discovery and development of new drugs. *Biomarkers in Medicine* provides context and perspective on the dynamic and rapidly evolving discipline of biomarkers and their discovery, providing a platform for commentary and debate on the identification of biomarkers, elucidation of their role and formalization and approval of their application in medicine. The journal's audience includes industrial and academic scientists, clinicians, policy and decision makers, healthcare professionals and regulatory personnel.

*“Biomarkers in Medicine delivers high-quality information on important current topics in the rapidly evolving field of biomarkers. The journal provides authors the opportunity to convey both their opinions and expertise to a wide audience.”*

**Jozef Bartunek**, Cardiovascular Center, OLV Ziekenhuis, Belgium

## Coverage includes:

- Biomarkers in drug discovery and development, with pharmacokinetic/ pharmacodynamic modeling and simulation to refine drug development
- Optimum biomarker selection, validation and application with pharmacoepidemiology, pharmacogenetics, pharmacogenomics and functional proteomic techniques.
- Biomarkers for clinical safety assessment and predicting adverse effects
- Bioanalytical method development and validation
- Impact of biomarkers on medicine

## Indexing:

EMBASE/Excerpta Medica, Scopus®, EMBiology, Chemical Abstracts, BIOSIS Previews, BIOSIS Selective Coverage, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded (SciSearch®), Biotechnology Citation Index®, Journal Citation Reports/Science Edition, MEDLINE/Index Medicus

# Breast Cancer Management

ISSN: 1758-1923

Volume: Number 2 (2013)

Frequency: 6 issues per year



New in 2012

## Senior Editors

**Mike Dixon**, University of Edinburgh, UK

**V Craig Jordan**, Georgetown University Medical Center, USA

*Breast Cancer Management* provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. *Breast Cancer Management* addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. The journal's audience includes oncologists, surgeons, imaging specialists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Changes in breast cancer management have led to huge improvements in outcomes for patients. Continued improvements in treatments require a journal like Breast Cancer to disseminate the most effective management strategies for this common disease."*

**Mike Dixon**, University of Edinburgh, UK

## Coverage includes:

- Diagnosis and imaging
- Surgical approaches
- Radiotherapy
- Systemic therapies
- Cancer clinical trials



# Clinical Lipidology

ISSN: 1758-4299

Volume: Number 8 (2013)

Frequency: 6 issues per year

Impact Factor: 0.754 (2011)



Lipid-related illnesses are set to impose a huge burden on healthcare in the coming years, with lipids playing an important role in many areas of research. *Clinical Lipidology* reports on the major advances in lipidology research and assists the health community in meeting these challenges. *Clinical Lipidology* aims to provide a forum for new clinical findings, therapeutic overviews of optimal treatment strategies, as well as cutting-edge translational research; it aims to provide the increasingly time-strained scientific community with an accessible and definitive resource covering all aspects of lipids in health and disease. The journal's audience includes cardiologists, lipidologists, hematologists, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Clinicians need a concise, up-to-date resource to guide them in decision making. Clinical Lipidology brings vital information to practitioners in a concise, comprehensive way."*

**Karol Watson**, David Geffen School of Medicine, USA

## Coverage includes:

- The genetics and molecular biology of lipid disorders and metabolism
- Related cardiovascular diseases, such as atherosclerosis
- Obesity and the metabolic syndrome
- Results of recent clinical trials relevant to the field of lipidology
- Treatment of lipid-related disorders and side effects of lipid-lowering medication

## Indexing:


EMBASE/Excerpta Medica, Chemical Abstracts, EMBiology, Science Citation Index Expanded™ (SciSearch®), Journal Citation Reports/Science Edition®, Scopus®

# Clinical Practice

ISSN: 2044-9038

Volume: Number 10 (2013)

Frequency: 6 issues per year



## Senior Editors

**Gregory YH Lip**, City Hospital, Birmingham, UK

**James Larkin**, The Royal Marsden Hospital, London, UK

**Samy I McFarlane**, SUNY Downstate, New York, USA

*Clinical Practice* provides a forum to address key issues across medical practice by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in day-to-day situations. The journal addresses all aspects facing clinical practitioners today, from exploring unmet therapeutic needs to analyzing the implications of real-world evidence, applications of clinical guidelines and multidisciplinary approaches to care. The journal's audience includes clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Clinical Practice is exciting and unique because it cuts across the whole of the medical field, providing detailed but incisive coverage of relevance to practising clinicians.”*

**James Larkin**, Royal Marsden Hospital, London, UK

## Coverage includes:

- Application of Phase III clinical trial results in clinical practice
- Understanding of unmet clinical needs and therapeutic burden
- Practical approaches to disease management
- Evidence-based treatment guidelines
- Multidisciplinary team approaches to care

## Indexing:


EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®

# CNS Oncology

ISSN: 2045-0907

Volume: Number 2 (2013)

Frequency: 6 issues per year



New in 2012

## Senior Editors

**Alba A Brandes**, AUSL Bologna, Italy

**Henry S Friedman**, Duke University Medical Center, NC, USA

*CNS Oncology* addresses key issues and current understanding in the diagnosis, staging and treatment of disease by exploring the best patient-centered clinical research and presenting this information in a succinct format of direct relevance in the clinic. *CNS Oncology* provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances in clinical practice in the field are reported and analyzed by international experts, and the importance of the most recent advances in molecular biology are explained. The journal's audience includes oncologists, neurologists, neurosurgeons, imaging specialists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"There is no question that much work needs to be done in neuro-oncology and CNS Oncology hopes to play a major role in disseminating this information to a broad constellation of physicians and scientists involved in the neuro-oncology field."*

**Henry S Friedman**, Duke University Medical Center, USA

## Coverage includes:

- Diagnosis and treatment of all tumors of the CNS, including glioblastoma multiforme, medulloblastoma, astrocytoma, ependymoma, meningioma and metastases
- Applications of imaging in diagnosis and treatment
- Radiotherapy, chemotherapy and surgical approaches to treatment
- Advances in the use of biomarkers for diagnosis and measuring treatment response
- Risk and prevention




# Colorectal Cancer

ISSN: 1758-194X

Volume: Number 2 (2013)

Frequency: 6 issues per year



New in 2012

## Senior Editor

**Heinz-Josef Lenz**, University of Southern California, USA

Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. *Colorectal Cancer* presents reviews, analysis and commentary on all aspects of colorectal cancer, providing a concise, readable overview of current and future management options in a fast-moving field, ideal for the busy clinician or healthcare professional. The journal's audience includes oncologists, surgeons, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"The complexity of diagnostics and therapeutic decision making in colorectal cancer management warrant special expertise. Colorectal Cancer provides both useful information for the clinical user, and a great platform for discussion of basic research and its implications for the upcoming strategies."*

**Dirk Arnold**, Medical Director of the Hubertus Wald Tumor Center, University Cancer Center Hamburg, Germany

## Coverage includes:

- Hereditary conditions
- Screening and diagnosis
- Surgery, radiation and chemotherapy
- Prospects for new treatments
- Risk factors, prevention and follow-up care for colorectal cancer survivors




# Diabetes Management

ISSN: 1758-1907

Volume: Number 3 (2013)

Frequency: 6 issues per year



## Associate Editors

**Denis Daneman**, University of Toronto, Canada

**Philippe Froguel**, Imperial College London, UK

**Camillo Ricordi**, University of Miami, USA

**Jaakko Tuomilehto**, University of Helsinki, Finland

*Diabetes Management* offers systematic coverage of the very latest advances in the treatment and prevention of diabetes mellitus, including molecular, genetic and physiological aspects. Through a unique mixture of reviews, perspectives and original research, *Diabetes Management* provides cutting-edge perspectives on Type 1 and Type 2 diabetes. The journal's audience includes diabetologists, endocrinologists, general practitioners, nurse specialists, pharmacologists, ophthalmologists, podiatrists, dieticians, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel affairs.

*“Diabetes Management is a forum to provide useful and novel information to those who are in contact with people with diabetes worldwide. Owing to the concept of focused peer reviewed articles and brief summaries, it allows any professional to be informed about the unbiased view of the leading researchers and clinicians.”*

**Jaakko Tuomilehto**, University of Helsinki, Finland

## Coverage includes:

- Prospects for new therapeutic approaches
- Pathogenesis of diabetes and its complications
- Pharmacological mechanisms of drug and hormone action
- Diabetes as a risk factor, and complications of disease
- Pharmacoeconomic issues and outcomes studies

## Indexing:

Chemical Abstracts





# Future Cardiology

ISSN: 1479-6678

Volume: Number 9 (2013)

Frequency: 6 issues per year



Research advances have contributed to improved outcomes across all medical specialties but the rate of advancement in cardiology has been exceptional. Exciting developments in electrical and mechanical devices, cell therapy and xenotransplantation, coupled with a growing understanding of cardiac function and disease, are already delivering real benefits. *Future Cardiology* provides a forward-looking authoritative perspective to inform future clinical practice in cardiovascular care. Integrated molecular approaches will have a greater impact on cardiovascular healthcare in the future; however, the expense of such treatments viewed alongside the increasing aging population will require a review of how this care is provided and explores their relevance in the clinical setting, to inform future clinical practice in cardiovascular care. The journal's audience includes cardiologists, lipidologists, hematologists, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Future Cardiology has delivered on its promise to bring contemporary high-quality and relevant topics in cardiovascular disease to the reader on a broad range of topics. Where many cardiovascular journals have become specialised, Future Cardiology remains broad in scope."*

**Farack Mookadam**, Mayo Clinic, USA

## Coverage includes:

- Molecular basis of cardiovascular disease
- Therapeutic overviews highlighting optimal therapies and future options
- Interventional, surgical and psychosocial aspects of cardiovascular disease
- Novel therapeutics and combination medicines, including pharmacoeconomic and outcomes issues in cardiology
- Advances in diagnostics

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®



# Future Microbiology

ISSN: 1746-0913

Volume: Number 8 (2013)

Frequency: 12 issues per year

Impact Factor: 3.819 (2011)



There is a striking prevalence and diversity of microbial pathogens including bacteria, fungi, parasites, prions and viruses, which present an ever-increasing healthcare burden. Thus, understanding the infectious strategies employed by pathogens and translating this knowledge into effective diagnostics and treatments for these diseases is key. *Future Microbiology* provides an interdisciplinary forum to debate findings and opinions for all scientists working in the field today, bringing together the diverse subject areas of bacteriology, mycology, parasitology and virology. The journal's audience includes clinicians specializing in infectious diseases, microbiologists, bacteriologists, immunologists, mycologists, parasitologists, virologists, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Future Microbiology provides a cutting-edge perspective on the novel concepts and technological opportunities in the fight against microbial diseases in the post-genomic era.”*

**Marc Struelens**, Université Libre de Bruxelles, Belgium

## Coverage includes:

- Pathogenetic mechanisms of microbial diseases and microbe–host interactions
- The evolution and molecular epidemiology of pathogens, including zoonotic, hypervirulent and re-emerging microbes impacting human health
- Optimal therapeutic approaches against infection, including methods for detecting, monitoring and treating drug-resistant infections
- Methods for detection of pathogens and diagnosis of infection
- The use of microbes in the treatment of disease and genetic engineering

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, CAPCAS, EMBiology, Biobase, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus®



# Future Neurology

ISSN: 1479-6708

Volume: Number 8 (2013)

Frequency: 6 issues per year



*Future Neurology* publishes original research together with authoritative commentary and analysis to address the important challenges and advances arising in the translation of laboratory advances into the clinic in neurology. *Future Neurology* delivers this essential information in concise, at-a-glance article formats – vital for delivering information to an increasingly time-constrained community. The journal's audience includes neurologists, neurosurgeons, neurophysiologists, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Future Neurology brings essential information in a highly authoritative compact format, anticipating and fulfilling the needs of neurologists.”*

**George Perry**, The University of Texas at San Antonio, USA

## Coverage includes:

- Pathophysiological mechanisms involved in neurological dysfunction
- Novel targets for disease therapy
- Clinical implications and applications for biomarkers of disease
- Genetic contributions to neurological disorders
- Impact of molecular genetics on prevention, screening, diagnosis and treatment

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®



# Future Oncology

ISSN: 1479-6694

Volume: Number 9 (2013)

Frequency: 12 issues per year

Impact Factor: 3.163 (2011)



*Future Oncology* provides an important forum for the clinical and scientific oncology community as we enter a new era of cancer care. The journal focuses on the most important advances and explores their relevance in the clinical setting, providing authoritative, cutting-edge and relevant information. *Future Oncology* publishes reviews, perspectives, original research studies and more. The journal's audience includes oncologists, hematologists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Future Oncology is pushing the frontier for clinicians and scientists with innovative, thoughtful and provocative publications."*

**Nathan Lawrentschuk**, Ludwig Institute for Cancer Research and University of Melbourne, Australia

### Coverage includes:

- Impact of molecular genetics on prevention, screening, diagnosis and treatment
- Pharmacoeconomics and cost–benefit issues in cancer
- Adverse events and drug safety
- Profiles of new anticancer agents
- Selective and 'personalized' approaches, integrating diagnostic and therapeutic approaches

### Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Scopus®



# Future Virology

ISSN: 1746-0794

Volume: Number 8 (2013)

Frequency: 12 issues per year

Impact Factor: 1.21 (2011)



Advances in genomics are revealing a host of new insights into viral biology: from phylogenetics and epidemiology to the molecular basis of disease; antiviral development to novel diagnostics. *Future Virology* uses clear and concise article formats to provide a forum for international experts to present their findings and to discuss and evaluate all aspects of virology. In addition, HIV-focused material is included in each issue, highlighting the fundamental research, clinical challenges, social consequences and disease management issues in this important area of research. The journal's audience includes virologists, infectious disease specialists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Anyone who wants to stay abreast of ongoing developments in our field should read Future Virology on a regular basis."*

**Mark A Wainberg**, McGill University, Canada

## Coverage includes:

- Virus–host interactions, and the molecular basis of viral disease
- Overviews highlighting optimal therapeutic and diagnostic approaches
- Antiviral agents and viral drug resistance
- Vaccine development and the prevention of viral disease
- The use of viral vectors in gene therapy and functional genomics

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, CAPCAS, EMBiology, Biobase, Science Citation Index Expanded™ (SciSearch®), Journal Citations Report/Science Edition®, Scopus®




# Imaging in Medicine

ISSN: 1755-5191

Volume: Number 5 (2013)

Frequency: 6 issues per year



## Senior Editor:

**Elliot K Fishman**, Professor of Radiology and Oncology, Johns Hopkins Hospital, USA

*Imaging in Medicine* provides highly structured commentary and analysis regarding advanced imaging technologies and applications. It presents original research findings, publishes comprehensive profiles of imaging techniques, technologies and the materials used in the clinical and drug research settings, and explores risk issues and societal issues. The journal's audience includes medical physicists, biomedical engineers, biophysicists, radiologists, cardiologists, neurologists, imaging practitioners, biochemists, biologists, chemists, technicians, surgeons, pathologists, computer scientists, physiologists and other physicians with special interests in imaging.

*"Imaging in Medicine provides cutting-edge articles that are of critical importance to the practicing radiologist. The articles are written and presented in a user-friendly format and are a critical part of lifelong learning."*

**Elliot K Fishman**, John Hopkins School of Medicine, USA

## Coverage includes:

- Clinical applications of imaging technologies – guidelines, experience and best practice
- Computed tomography, MRI, PET and sonography
- Translation of technological advances into clinical practice
- Transition from structural to functional imagery
- Imaging applications in drug discovery, diagnostics and personalized medicine

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®


# Immunotherapy

ISSN: 1750-743X

Volume: Number 5 (2013)

Frequency: 12 issues per year

Impact factor: 1.854 (2011)



## Senior Editors:

**Yutaka Kawakami**, Keio University School of Medicine, Japan

**Francesco M Marincola**, National Cancer Institute, USA

**David C Wraith**, University of Bristol, UK

Many aspects of the immune system and mechanisms of immune-modulated therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. *Immunotherapy* offers the scientific community an interdisciplinary forum, providing them with concise and recent advances of various aspects of immunotherapeutics to aid navigation of this complex field. The journal's audience includes immunologists, vaccinologists, oncologists, allergists, clinicians specializing in autoimmune diseases, transplant clinicians, academic and pharmaceutical scientists, policy and decision makers, epidemiologists, healthcare professionals and regulatory personnel.

*"Immunotherapy keeps me current on every aspect of vaccines from AIDS to allergy. A must read for all scientists involved in the cutting-edge development of immunotherapeutics."*

**Kim D Janda**, The Scripps Research Institute, CA, USA

## Coverage includes:

- Cancer immunotherapy, including cancer vaccines and passive immunotherapeutic approaches
- Suppressive immunotherapy for autoimmune diseases and transplantation
- Drug-immune system interactions
- Summaries evaluating newly approved immunotherapeutic agents
- Newly identified immune targets of drugs

## Indexing:

MEDLINE/Index Medicus, Chemical Abstracts, EMBASE/Excerpta Medica, Science Citation Index Expanded (SciSearch®), Journal Citation Reports/Science Edition, Biological Abstracts, BIOSIS Previews



# International Journal of Hematologic Oncology

**ISSN:** 2045-1393

**Volume:** Vol 2 (2013)

**Frequency:** 6 issues per year



New in 2012

Leukemia, lymphoma and myeloma, taken together, represent the fifth most commonly occurring cancers and the second leading cause of cancer death. Symptoms of the disease are varied, with some forms of the disease being aggressive and others benign. The discovery of new targeted therapies, advances in chemotherapy and the development of new combination drugs, along with important emerging research, have contributed to the significant progress made within the field of hematologic oncology in recent years.

*International Journal of Hematologic Oncology* is dedicated to presenting the latest and most promising developments and discoveries in the study of hematologic malignancies and its related fields. The journal provides a forum for the discussion and analysis of emerging advances in diagnosis, treatment strategies and novel targeted therapies, with an added focus on overall management of hematologic malignancies and evaluation of prospects for further development. This peer reviewed journal will publish a range of concise, authoritative reviews by leading experts, as well as topical commentary and analysis. The audience includes hematologists, oncologists, imaging specialists, pharmacologists, and policy and decision makers, in addition to clinicians, researchers, personnel involved with end-of-life care and other specialists working in the field of hematological oncology.

*“International Journal of Hematologic Oncology promises to be an exciting new resource for clinicians and researchers alike, with comprehensive and timely coverage of topics within the field”.*

**Stefano Molica**, Azienda Ospedaliera Pugliese-Ciaccio, Italy

## Coverage includes:

- All forms of hematologic malignancies including leukemia, lymphoma, myeloma and related diseases
- Epidemiology and pathology of the disease types
- Medical oncology – the diagnosis and management of hematologic cancers
- Imaging, radiology and chemotherapy
- Prospects for new treatments such as stem cell therapy and immunotherapy








# Interventional Cardiology

ISSN: 1755-5302

Volume: Number 5 (2013)

Frequency: 6 issues per year



## Senior Editors:

**Eberhard Grube**, Division of Structural Heart Disease, International Heart Centre Rhein-Ruhr, Germany

**Ron Waksman**, Division of Cardiology, & Experimental Angioplasty & Emerging Technologies for the Cardiovascular Research Institute (CRI), Washington Hospital Center, USA

The field of interventional cardiology continues to be characterized by innovation and technological progress. Clinicians, in partnership with specialists in molecular biology, biomedical engineering, biophysics and imaging technology, have evolved this field into one of the most vibrant and dynamic subspecialties in mainstream medical practice. *Interventional Cardiology* charts the advances of this vibrant and dynamic subspecialty and provides a unique resource for interventionalists seeking to keep pace with the unfolding technologies. *Interventional Cardiology* provides a forum for commentary, debate and new findings as the scope for the potential application of these technologies becomes increasingly complex. The journal's audience includes interventional cardiologists, cardiologists, surgeons, radiologists, pharmacologists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"In a clear and concise manner Interventional Cardiology effectively and cohesively delivers a diverse spectrum of current informative material to a global audience."*

**Ron Waksman**, Washington Hospital Center, USA

## Coverage includes:

- Diagnostic and imaging technologies
- Angioplasty and stenting (i.e., drug-eluting stents, catheterization techniques)
- Percutaneous mitral valve replacement and repair in addition to endovascular repair
- Treatment of arrhythmias, including cardiac resynchronization and pacing devices
- Cell therapy

## Indexing:

EMBASE/Excerpta Medica



# Journal of Comparative Effectiveness Research

ISSN: 2042-6305

Volume: Number 2 (2013)

Frequency: 6 issues per year



New in 2012

## Senior Editors:

**Sheldon Greenfield**, Health Policy Research Institute, University of California, USA

**Eugene Rich**, Center on Health Care Effectiveness, Mathematica Policy Research, USA

Through rigorous evaluation and comprehensive coverage, *Journal of Comparative Effectiveness Research* provides stakeholders (including patients, clinicians, healthcare purchasers and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice. The journal's audience includes patients, clinicians, healthcare purchasers and health policy makers.

*“Journal of Comparative Effectiveness Research provides a valuable resource for all stakeholders interested in both methodologic advancements and research findings in this important and burgeoning field.”*

**Sheldon Greenfield**, University of California, USA

## Coverage includes:


- Studies of effectiveness or comparative effectiveness and safety yielding new findings relating to diagnostics, therapeutics, surgical procedures, or other healthcare services or options
- Narrative and systematic reviews of available evidence relating to the pros and cons of healthcare options for specific patient groups
- Perspectives and debate relating to the performance of comparative effectiveness studies and best practice issues
- Commentary on both patient-relevant outcomes, pharmacoeconomics, health economics and outcomes research
- Direct ‘head-to-head’ comparisons of available diagnostic and therapeutic options – evaluating clinical alternatives with current standard of care

# Lung Cancer Management

ISSN: 1758-1966

Volume: Vol 2 (2013)

Frequency: 6 issues per year



New in 2012

## Editor-in-Chief

**David J Sugarbaker**, Brigham and Women's Hospital, MA, USA

The strong link between smoking rates and lung cancer incidence has resulted in varying rates of disease within different populations whether on a geographic, socioeconomic or gender basis. What is clear is that, in spite of declining disease rates among some groups in certain developed countries, the disease remains a highly significant global burden. For example, the US National Cancer Institute has estimated that the national cost of lung cancer treatment exceeds \$10 billion.

*Lung Cancer Management* provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances in clinical practice within the field are reported and analyzed by international experts, and the importance of the most recent advances in our understanding of lung cancer molecular biology are explained. The journal's audience includes oncologists, surgeons, imaging specialists, clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"The most highly integrated clinical and research journal for lung cancer management and therapy."*

**David Sugarbaker**, Brigham and Women's Hospital, USA

## Coverage includes:

- Diagnosis, biomarkers and imaging
- Pharmacoeconomics and comparative effectiveness
- Chemotherapy, radiotherapy and surgical approaches
- Biological and systemic therapies
- Risk and prevention






# Neurodegenerative Disease Management

ISSN: 1758-2024

Volume: Number 3 (2013)

Frequency: 6 issues per year



## Associate Editors:

**Anthony H Schapira**, Department of Clinical Neuroscience at the UCL Institute of Neurology and Chairman of Clinical Neurosciences Specialties, University College London, UK

**Bruno Dubois**, The Cognitive Neurology Department and the Alzheimer's Center, Hospital La Salpêtrière, France

The prevention and treatment of neurodegenerative disorders represents a critical goal for current medical research teams. Bringing together the latest commentary and analysis from across a broad spectrum of practice and research, *Neurodegenerative Disease Management* promotes a truly multidisciplinary approach to developing new treatments for neurodegenerative diseases. The journal's audience includes neurologists, neuroscientists, gerontologists, general practitioners, pharmacologists, occupational therapists, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel affairs.

*"Neurodegenerative Disease Management is at the cross-road of clinical research and management of patients. It provides a very useful update for demanding clinicians."*

**Bruno Dubois**, Hospital La Salpêtrière, France

## Coverage includes:

- Evaluation of current and future pharmacological therapies
- Nonpharmacological management strategies
- Clinical utility of diagnostics, biomarkers and imaging
- Approaches to caregiving and palliative care
- Epidemiology and the genetics underlying disease






# Pain Management

ISSN: 1758-1869

Volume: Number 3 (2013)

Frequency: 6 issues per year



## Senior Editors:

**Martin Grabois**, Professor and Chairman, Baylor College of Medicine, USA

**Andrew SC Rice**, Professor of Pain Research, Imperial College London, UK

This peer reviewed, multidisciplinary journal provides a forum for commentary and debate for a growing community of pain specialists. Bringing together the latest research findings and reviews in pain medicine and pain management, this journal is a vital addition to the literature. The audience includes anesthesiologists, neurologists, physiatrists, psychiatrists, personnel working within pain clinics and other specialists with an interest in the development and application of approaches to pain management. The journal's audience includes neurologists, neuroscientists, anaesthetists, general practitioners, nurse specialists, pharmacologists, palliative care specialists, psychologists, orthopedic and rheumatology specialists, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel affairs.

*"Now in its third volume, Pain Management continues to publish timely and comprehensive articles on a wide variety of topics. It is indeed a valuable resource to practitioners and academics alike."*

**Andrew Rice**, Imperial College London, UK

## Coverage includes:

- Treatments and techniques in interventional pain management and pain medicine
- Advances and breakthroughs in the treatment of chronic and acute pain
- Cancer, neuropathy and referred pain
- Novel methods in drug application for pain management
- Future role of personalized medicine in the development of therapeutics for pain





# Personalized Medicine

ISSN: 1741-0541

Volume: Number 10 (2013)

Frequency: 8 issues per year

Impact Factor: 1.528 (2011)



*Personalized Medicine* translates recent genomic, genetic and proteomic advances into the clinical context, and addresses the impact of pharmacogenomics in modern medicine, providing an integrated forum for all players involved in the healthcare value chain.

The journal addresses scientific, commercial and policy issues in personalized medicine and includes news and views, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to *Personalized Medicine* are subject to rigorous peer review. The journal's audience includes specialists in molecular diagnostics, pathologists, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Personalized Medicine provides a well-balanced perspective in the midst of the cacophony of omic-based advances. It is a must read for all who wish to practice 22nd century medicine."*

**Charis Eng**, Cleveland Clinic Foundation Genomic Medicine Institute, USA

## Coverage includes:

- Advances in molecular diagnostics with respect to individualizing medicine
- Cost-benefit issues for personalized medicine
- Impact of personalized medicine on healthcare and the pharmaceutical industry
- Impact of the latest concepts in the development of personalized medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics

## Indexing:

EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, Scopus®



# Regenerative Medicine

ISSN: 1746-0751

Volume: Number 8 (2013)

Frequency: 6 issues per year

Impact Factor: 3.718 (2011)



## Senior Editor:

**Chris Mason**, Professor of Regenerative Medicine Bioprocessing, University College London, UK

Apart from answering some of the most fundamental questions of biology and stem cell research, regenerative medicine offers unprecedented opportunities for developing new medical therapies for debilitating and life-threatening diseases. *Regenerative Medicine* is the forum for a fast-growing community of specialists to address the important challenges and advances that are now occurring in stem cell research and regenerative medicine. It delivers this essential information in concise, clear and attractive article formats. The journal's audience includes regenerative medicine scientists, tissue engineers, research clinicians, scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*“Regenerative Medicine is the leading international publication exclusively committed to the advancement of cell-based therapies. Contained within its pages is the very latest science, clinical translation and commercialization, a one-stop shop for regenerative medicine information.”*

**Chris Mason**, University College London, UK

## Coverage includes:

- Bench-to-bedside translation and scale-up of stem cell and regenerative medicine therapies
- Potential applications for stem cell-based strategies in pathological conditions
- Tissue engineering and characterization of engineered tissues
- Regulatory and reimbursement issues
- Ethical and legal perspectives

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus®

# Women's Health

ISSN: 1745-5057

Volume: Number 9 (2013)

Frequency: 6 issues per year



Women's physiology and hormonal changes across the life cycle demand important consideration when determining healthcare management options in certain diseases. Age- and gender-related factors can directly affect treatment outcomes. There are also certain conditions that are far more prevalent in women than men and these may require special attention. *Women's Health* provides the forum for commentary and analysis of those diseases and conditions that are of critical importance to women for an audience of clinicians, research scientists, decision-makers and a range of professionals in the healthcare community. The journal's audience includes gynecologists, obstetricians, oncologists, specialists in women's health clinics, clinicians, research clinicians, academic and pharmaceutical scientists, policy and decision makers, healthcare professionals and regulatory personnel.

*"Women's Health provides up-to-date and concise reviews of topics that cover all aspects of women's health from menarche to post-menopause. It's a really useful resource for the busy clinician."*

**William Ledger**, University of New South Wales, Australia

## Coverage includes:


- Current and emerging topics relating to the safe and effective management of therapy in women
- Original research articles presenting the latest clinical findings
- Women-specific cancers
- Other women-specific conditions, such as reproductive health, to embrace the unique pathophysiology of disease in women and the corresponding effect on treatment
- Gender difference issues in medicine

## Indexing:


MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, Chemical Abstracts, Scopus®

# eBooks

from future science group



Your ultimate resource  
for scientific research



Purchase individual eBooks  
online or contact us to set  
up your institutional trial to  
the whole collection

**visit:** [www.futuremedicine.com](http://www.futuremedicine.com)  
**contact:** [info@futuremedicine.com](mailto:info@futuremedicine.com)



High-quality  
commentary  
and analysis



# Future Science

“Revelations in R&D”

Future Science specializes in the publication of new findings and high-quality commentary and analysis in today's key areas of research endeavor. Coverage reflects those areas that most impact our daily lives, our infrastructure for sustainable development and the associated technologies that will allow society to co-exist in harmony with the environment

[www.future-science.com](http://www.future-science.com)

**FUTURE  
SCIENCE**



## Benefits of the Future Science series

**Timely reviews and high-quality original research:** This series of journals cover a broad range of scientific fields to ensure that your team is kept up-to-date on the latest advances and techniques.

**Highly structured format:** Each article provides a complete overview of current thinking on that topic of research, structured for accessibility.

**High-quality imagery and tabular data:** Produced to the highest production standards featuring our award-winning design, professional layout, high-quality images and graphically enhanced tabular data.

**Acclaimed authors and editorial boards:** **Future Science** journals are leading forums for debate in R&D and we work closely with our Senior Editors and expert advisory panels to identify leading authors and hot topics.

**Rigorous peer review and a dedicated in-house editorial team:** Our dedicated in-house editorial team ensures that we publish the most relevant topics, all within industry-leading time frames. Each article is subject to rigorous peer review by three independent experts, to ensure quality and accuracy at all times.

**High visibility:** Our journals are indexed on many of the leading abstracting services including ISI Science Citation Index, MEDLINE, EMBASE and Chemical Abstracts. See individual journals for full details.

**Rapid publication:** We offer rapid publication as standard, ensuring the most up-to-date information is processed.

# Contents

A background image featuring a complex molecular structure with grey spheres representing atoms and black lines representing bonds. The structure is set against a light, warm-toned background with soft, out-of-focus circular highlights, suggesting a scientific or technological theme.

Bioanalysis	63
Biofuels	64
Carbon Management	65
Clinical Investigation	66
Future Medicinal Chemistry	67
Pharmaceutical Bioprocessing	68
Pharmaceutical Patent Analyst	69
Therapeutic Delivery	70



# Bioanalysis

ISSN: 1757-6180

Volume: Number 5 (2013)

Frequency: 24 issues per year

Impact Factor: 3.223 (2011)



## Senior Editors:

**Brian Booth**, Division of Clinical Pharmacology 5, US FDA, USA

**Howard Hill**, Pharmaceutical Development, Huntingdon Life Sciences, UK

*Bioanalysis* is a fortnightly publication focusing on the development, implementation and performance of analytical techniques that enable scientists to obtain specific, selective, sensitive and reproducible data regarding a drug and its metabolites in biological samples. *Bioanalysis* delivers essential information in concise, at-a-glance article formats. Key scientific, technical and regulatory advances in the field are reported and analyzed by international experts, providing an authoritative and accessible forum for the modern bioanalyst. The journal's audience includes bioanalysts, analytical chemists, mass spectroscopists, chromatographers, pharmacologists, clinical chemists, analytical toxicologists, and those involved with studies of drug metabolism, pharmacokinetics, toxicity, bioequivalence and metabolomics.

*"Bioanalysis is more than just a journal dedicated to bioanalytical methodology, techniques and new technologies; it explores the understanding of why we do bioanalysis, what the external and internal influences are and what impact these have on the rapidly evolving field of bioanalysis. Reaching the worldwide community, Bioanalysis is all these and much, much more."*

**Howard Hill**, Huntingdon Life Sciences, UK

## Coverage includes:

- Innovative drug, metabolite and biomarker assays
- Analyte extraction and sample preparation
- Chromatography, ligand-binding assays, mass spectrometry and other key techniques
- Method development, validation, regulatory and compliance issues
- Diagnostic assays and test kits

## Indexing:


MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Scopus®

# Biofuels

ISSN: 1759-7269

Volume: Number 4 (2013)

Frequency: 6 issues per year



## Senior Editors:

**Yusuf Chisti**, Massey University, New Zealand

**Timothy Donohue**, University of Wisconsin-Madison, USA

Biofuel research is occurring at an unprecedented rate, with the development of new feedstocks and improvements in production processes providing the key to the transformation of biomass into a global energy resource. *Biofuels* provides a forum for all stakeholders in the bioenergy sector, featuring review articles, policy updates, original research articles, commentaries, news and interviews with key opinion leaders, and much more. The journal's audience includes academics, industry professionals, scientists, economists, policy- and decision-makers, bioenergy stakeholders and non-governmental organizations.

*"Biofuels insightfully covers all that matters – production and use, socioeconomic aspects, policy issues, environmental impact of production and use, sustainability considerations, national and regional scenarios, emerging knowledge, and more."*

**Yusuf Chisti**, Massey University, New Zealand

## Coverage includes:

- Sustainable production of annual, perennial and wood feedstocks from agriculture
- Creation of new bioenergy sources
- Biochemical conversion and engineering techniques
- Fermentation, anaerobic digestion and enzyme development
- Policy and management issues for the establishment of a global bioenergy market

## Indexing:

CAB Abstracts, Compendex, El Encompass, Scopus®, Chemical Abstracts




# Carbon Management

ISSN: 1758-3004

Volume: Number 4 (2013)

Frequency: 6 issues per year



## Senior Editors:

**Shobhakar Dhakal**, National Institute for Environmental Studies, Japan

**Richard A Houghton**, Senior Scientist, Woods Hole Research Center, USA

*Carbon Management* examines the mechanisms by which we can both manage current GHG levels and reduce future emissions effectively, to mitigate climate change. The journal covers opportunities for carbon management throughout the whole carbon cycle, including technological and engineering innovations for carbon sequestration, as well as the role of natural processes. Plans aimed at managing and reducing emitted carbon, such as carbon accounting initiatives, also feature. The journal's audience includes academics, industry professionals, scientists, economists, policy- and decision-makers, bioenergy stakeholders and non-governmental organizations.

*“Carbon Management has attracted considerable attention in the scientific community as it gives a common platform to otherwise disparate disciplines. It also provides an urgently needed outlet for interdisciplinary research, so vital to meeting the challenges of global environmental change.”*

**Johannes Lehman**, Cornell University, USA

## Coverage includes:

- Natural cycles, sinks and sources of carbon and other greenhouse gases in relation to terrestrial, aquatic, marine and atmospheric environments
- Modeling of carbon emissions and management scenarios for multiple climate stabilization targets
- The impacts of anthropogenic activities on carbon emissions
- Market-based mechanisms of emission reductions and management processes at local, regional and national levels
- Policy developments to regulate, incentivize and account for reductions in carbon emissions

## Indexing:

CAB Abstracts, Compendex, El Encompass, Scopus®, Chemical Abstracts



# Clinical Investigation

ISSN: 2041-6792

Volume: Number 3 (2013)

Frequency: 12 issues per year



## Senior Editor:

**E Michael Lewiecki**, New Mexico Clinical Research & Osteoporosis Center, USA

*Clinical Investigation* is dedicated to systematic coverage of the design, methodology, progress and outcomes of clinical trials. As a peer reviewed, monthly publication *Clinical Investigation* provides a forum for the rapid publication of original research and critical reviews examining the latest developments in medical research, from Phase I trials through to postmarketing studies and pharmacoeconomic research. *Clinical Investigation* provides a systematic program of peer reviewed coverage relating to the clinical evaluation of new and established therapies. The audience for *Clinical Investigation* includes clinical investigators, healthcare decision makers, formulary managers, clinicians, regulatory personnel and medical affairs professionals.

*“Clinical Investigation has now become an established and very valuable source of information on clinical trials and outcome assessment in all areas of medicine”*

**Emilio Perucca**, University of Pavia, Italy

## Coverage includes:

- Clinical study design, methodology and regulatory issues
- Overviews of the clinical progress of new drugs or drug classes
- Commentary on in progress trials and findings in Phase I–IV clinical studies
- Clinical trial data management, statistics, outcomes and pharmacoeconomics
- Drug safety issues and adverse event monitoring

## Indexing:

Chemical Abstracts


# Future Medicinal Chemistry

**ISSN:** 1756-8919

**Volume:** Number 5 (2013)

**Frequency:** 18 issues per year

**Impact Factor:** 2.522 (2011)



## Senior Editors:

**Iwao Ojima**, Institute of Chemical Biology and Drug Discovery, Stony Brook University, USA

**David Thurston**, Department of Pharmacy, King's College London, UK

*Future Medicinal Chemistry* offers a forum for the rapid publication of original research and critical reviews covering the latest milestones in the field – from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. The journal is a valuable reference, not only for medicinal chemists, but for all those interested in the advancement of pharmaceutical science. The journal's audience includes chemists, medical professionals, academics, executives, senior scientists, bench scientists and other researchers in industry and academia.

*“Future Medicinal Chemistry provides a fresh, much-needed platform for the dissemination of succinct reviews and original research in medicinal chemistry.”*

**Brian SJ Blagg**, The University of Kansas, USA

## Coverage includes:

- Drug-discovery technologies
- Design and synthesis of novel lead compounds
- Computational approaches to synthesis and modeling
- Overviews of novel therapeutic strategies and emerging targets
- Commentary on science policy, economic, regulatory and IP issues

## Indexing:


MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Chemistry Citation Index®, Journal Citation Reports/Science Edition®, Scopus®

# Pharmaceutical Bioprocessing

ISSN: 2048-9145

Volume: Number 1 (2013)

Frequency: 6 issues per year (5 in 2013)



New in 2013

## Senior Editor:

**Professor Nigel Slater**, Cambridge University, UK

*Pharmaceutical Bioprocessing* provides an authoritative forum for insights into the latest advances in the design and development of production systems and processes for the generation of pharmaceutical products – from manufacturing to purification, through to the assessment and preparation of the final product for patient delivery. Coverage encompasses the full scope of pharmaceutical production, including vaccines, antibiotics and regenerative medicine therapies. By publishing high-impact reviews, perspectives and original research covering all aspects of this rapidly evolving area of R&D, *Pharmaceutical Bioprocessing* serves the needs of the associated multidisciplinary industrial and academic communities. Each issue of the journal also features news updates, editorials, and interviews, presenting enlightened opinion and commentary on hot topics and current areas of debate. The journal's target audience comprises molecular biologists, process engineers, biochemical engineers, microbiologists, manufacturing specialists and other professionals committed to the development of robust scaleable techniques, equipment and systems.

## Coverage includes:


- Process design, development, scale-up and automation
- Cell expression systems for biopharmaceutical production
- Upstream and downstream processing
- Production of recombinant proteins, monoclonal antibodies, vaccines and cell therapies
- Bioformulation, validation, regulation and patient delivery
- Regulatory issues and other areas of debate

# Pharmaceutical Patent Analyst

ISSN: 2046-8954

Volume: Number 2 (2013)

Frequency: 6 issues in 2013



New in 2012

## Senior Editors:

**Lyn Jones**, Pfizer, USA

**David Rotella**, Montclair State University, USA

*Pharmaceutical Patent Analyst* is dedicated to making the essential content of key patents available in a concise and enriched format to researchers and other specialists, while also providing timely commentary on important issues related to patent and IP law. The journal's core content therefore comprises high-impact patent reviews that provide an objective and concise appraisal of selected patents in a chosen area, set within the context of the wider relevant R&D landscape. Articles exploring patenting trends as well as those examining new methodologies for searching the patent literature also feature. Complementing the core scientific review content of each issue are news updates, editorials, interviews and hot topic articles presenting enlightened opinion and commentary on pressing IP issues. The journal's audience includes researchers, clinicians, patent analysts, IP specialists, legal professionals and technology-transfer officers.

*"Pharmaceutical Patent Analyst provides a timely and comprehensive perspective on intellectual property issues critical to researchers, scientists and legal professionals. This makes the journal a unique source of key information that should be regular reading for all."*

**David Rotella**, Montclair State University, USA

## Coverage includes:

Reviews examining patents of relevance to all therapeutic areas will be accepted, including:


- Chemical and biological entities of therapeutic significance
- Healthcare products (e.g., medical devices and drug-delivery systems)
- Drug-discovery and design technologies
- Inventions in related disciplines (e.g., biotechnology and nanotechnology)

# Therapeutic Delivery

**ISSN:** 2041-5990

**Volume:** Number 4 (2013)

**Frequency:** 12 issues per year



In a highly competitive industry, *Therapeutic Delivery* provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The delivery community draws together disciplines such as biology, chemistry, pharmacology and pharmaceuticals, nanotechnology, physiology, materials science and engineering. *Therapeutic Delivery* serves this community with highly informed and structured coverage, including reviews, original research, perspectives, commentary and news features. The journal's audience includes clinicians, research scientists, pharmacologists, nanotechnologists, professionals, policy and decision makers, healthcare and regulatory affairs.

*"Therapeutic Delivery has carved a niche in providing in-depth reviews on advanced translational drug delivery research by both industrial and academic scientists."*

**David Brayden**, University College Dublin, Republic of Ireland

## Coverage includes:

- Delivery of small-molecule drugs, vaccines, radionuclides, proteins, peptides, genes, siRNA, nucleotides, stem cells and diagnostic probes
- Targeting at the molecular, cellular, organ and systemic levels
- Methods for enhancement of pharmacokinetic profiles and biodynamic and bioresponsive delivery
- Stimuli-triggered delivery, parenteral delivery and nanotechnology
- Intellectual property, competitor intelligence and partnering news

## Indexing:

MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Scopus®



# Subject Collections



ACTIONABLE INFORMATION | PIONEERING RESEARCH & TOPICAL REVIEWS | AWARD-WINNING LAYOUT & DESIGN | ACCLAIMED AUTHORS & EDITORIAL BOARDS | FAST PUBLICATION TIMES

## Your Complete Digital Library

The Future Science Group offers subject collections in key areas comprising a growing collection of journals and eBooks covering the latest developments and hottest topics in modern medicine and management.

Each subject collection forms a complete digital library in your specialist area and includes flagship MEDLINE-listed journals and other key titles from our Expert Reviews and Future Medicine journal collections.

To complement the pioneering journal coverage a new and exciting range of eBooks has recently been launched. Written by some of the world's leading experts, these new eBooks cover some of the most important and emerging areas in medicine. With rapid publication time, expert authors and an accessible format these are resources no researcher or library should be without.

See our pricing page for further details, or contact us at [info@future-science-group.com](mailto:info@future-science-group.com) to further discuss one of our subject collections.



Oncology

72



Neurology

73



Cardiology

74



Infection & immunology

75



## Oncology Collection

### Journals


- Expert Review Anticancer Therapy *MEDLINE indexed*
- Expert Review Hematology *MEDLINE indexed*
- Breast Cancer Management
- CNS Oncology
- Colorectal Cancer
- Future Oncology *MEDLINE indexed*
- Lung Cancer Management
- International Journal of Hematologic Oncology



### eBooks including:

- Advances in the Management of Triple-Negative Breast Cancer  
Clifford A Hudis & Tiffany A Traina
- Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia  
Michael J Keating & Constantine Tam
- Targeted Therapies for Castration-Resistant Prostate Cancer  
Peter T Scardino
- Targeted Therapies for Hepatocellular Carcinoma  
Luigi Bolondi
- Targeted Therapies for Renal Cell Carcinoma  
Ronald M Bukowski
- Advances in Neuroendocrine Tumor Management  
Kjell Öberg
- Advances in Bone Metastasis Management  
Piero Picci & Pietro Ruggieri
- Advances in Ovarian Cancer Management  
Peter E Schwartz
- Advances in Pancreatic Cancer Treatment  
Helmut Friess & Norbert Hüser
- Emerging Therapeutics for Melanoma  
Francesco M Marincola, Paolo A Ascierto & John M Kirkwood

...and many more




# Neurology Collection

## Journals

- Expert Review of Neurotherapeutics *MEDLINE indexed*
- CNS Oncology
- Future Neurology
- Neurodegenerative Disease Management
- Neuropsychiatry
- Pain Management

## eBooks including:

- Antidepressants & Major Depressive Disorder  
Dan J Stein
- Triptans for Migraine  
Hans-Christoph Diener & David W Dodick
- Pharmacological Treatments in Schizophrenia  
Matcheri S Keshavan
- Analgesics for Cancer Pain  
Frank Porreca & Tamara King
- Advances in Parkinson's Disease Management  
Joseph Friedman
- Advances in Antiepileptic Drug Development  
Philip N Patsalos
- Critical Care in Spinal Cord Injury *New in 2013*  
Michael G Fehlings
- Stroke Management and Recovery *New in 2013*  
Bruce Ovbiagele
- Best Practices in Neurological Care *New in 2013*  
Bruce Ovbiagele
- Deep Brain Stimulation: Technology and Applications *New in 2013*  
Jerrold L Vitek



...and many more




## Cardiology Collection

### Journals


- Expert Review of Cardiovascular Therapy *MEDLINE indexed*
- Clinical Lipidology *MEDLINE indexed*
- Future Cardiology
- Interventional Cardiology

### eBooks

- Stroke Prevention in Atrial Fibrillation  
Harry J Crijns & Ron Pisters
- Advances in Heart Failure Management  
Henry Krum & Thomas G Von Lueder
- Clinical Applications of Renin–Angiotensin System Inhibitors  
Michel Burnier
- Advances in Acute Coronary Syndrome Management  
Harvey D White
- Management of Hypertension in Diabetes  
Samy I McFarlane
- New Oral Anticoagulants  
Jawed Fareed
- Drug-Eluting Stents  
Imad Sheiban & Fabrizio D'Ascenzo
- Peripheral Vascular Disease: Basic and Clinical Perspectives *New in 2013*  
Erich Minar & Martin Schillinger
- Hypertension *New in 2013*  
Ernesto L Schiffrin & Rhian M Touyz
- Advances in Myocardial Infarction Management *New in 2013*  
Jan Paul Ottervanger



...and many more



# Immunology/Infectious Disease Collection

## Journals

- Expert Review of Anti-infective Therapy *MEDLINE indexed*
- Expert Review of Clinical Immunology *MEDLINE indexed*
- Expert Review of Vaccines *MEDLINE indexed*
- Future Microbiology *MEDLINE indexed*
- Future Virology
- Immunotherapy *MEDLINE indexed*

## eBooks

- Novel Immunologic Adjuvants  
Rino Rappuoli & Ennio De Gregorio
- Human Papillomavirus Vaccines  
Eduardo L Franco
- Current & Emerging Treatments for Psoriasis  
Steven R Feldman
- Immunotherapeutic Agents for SLE  
Yehuda Shoenfeld, Pier Luigi Meroni & Ricard Cervera
- Addressing Unmet Medical Needs in Rheumatoid Arthritis  
Maurizio Cutolo
- Primary Care Management of Community-Acquired Pneumonia  
Thomas J Marrie
- Current & Emerging Diagnostics, Therapeutics & Vaccines for Tuberculosis  
Stefan HE Kaufmann
- Plant-derived Vaccines: Technologies & Applications  
Franco M Buonaguro
- Pneumococcal Conjugate Vaccines  
Ger T Rijkers
- Addressing Unmet Medical Needs in Relapsing–Remitting Multiple Sclerosis  
Richard A Rudick & Robert A Bermel



...and many more





# eBooks

from future science group

## Future Science Group eBooks – meeting the needs of the librarian

- Perpetual access and ownership
- NO DRM – users can choose how to access content
- Fully integrated into the library Catalogue
- Free MARC records
- COUNTER compliant usage statistics
- OpenURL compliance

### Future Medicine eBooks

With our industry-leading approach to high-quality content and production, the Future Medicine eBook series covers major topics of current medical/biological sciences. The Future Medicine eBook series will comprise over 100 titles by the end of 2013.

### Ask the Experts eBooks


Expert Reviews provides the essential guide to contemporary clinical medicine in their “Ask the Experts” series of eBooks. A consummate guide for healthcare professionals, the Ask the Experts series also supports the continuing education of experienced clinical caregivers and medical students looking to take the next step in their studies.

### Future Science eBooks

The Future Science eBook series aims to summarize and explore important and relevant areas of science in a digestible and accessible format. Launched in 2009, Future Science specializes in the publication of high-impact journals covering the latest advances in R&D – from medicinal chemistry, drug delivery and bioanalysis through to drug development through the clinical trial process, and beyond. The Future Science eBook series will continue this systematic coverage.

To obtain a full bibliographic listing, and access information please contact us directly at [sales@future-science-group.com](mailto:sales@future-science-group.com) or call us on +44 (0)20 8371 6080.

[www.future-science-group.com/ebooks](http://www.future-science-group.com/ebooks)



## Publishing solutions to accommodate all your publishing needs

### Service benefits

#### Editorial Support Service

- The editorial team are available to answer any pre-submission enquiries
- We will identify the journal that provides the optimal readership and return

#### Publication Support Service

- Our dedicated in-house editorial team will acknowledge your manuscript submission within 2 working days
- Decision on acceptance within 6 weeks of submission (or within 3 weeks for accelerated publication option)

### Accelerated publication

We offer an accelerated publication option for all articles ensuring that online publication is provided within 6 weeks of article submission. From initial submission to peer review, revision and production, our in-house team will ensure your article reaches a global audience within the minimum timeframe possible.

Please contact Laura Dormer at [l.dormer@future-science-group.com](mailto:l.dormer@future-science-group.com) if you would like further information on this option.

### Supplements

The Future Science Group publishes a number of supplements to our respected peer reviewed journals.

#### Supplements may comprise of:

- Symposia proceedings
- Abstract compilations
- Workshop summaries
- Article collections
- Roundtable discussions

#### Benefits include:

- Reach a wide-range of healthcare decision makers
- Raise awareness of latest research and product developments
- Enhance and increase the impact of a symposium



# publication SOLUTIONS

## Distribution options

In today's digital world reaching your target audience has never been easier. The Future Science Group offer a range of distribution options including CD-ROMs, USB sticks and webkeys. To discuss which distribution option will best meet your requirements please contact Laura Dormer at [l.dormer@future-science-group.com](mailto:l.dormer@future-science-group.com).

## Reprints & ePrints

Reprints and ePrints are a cost-effective and authoritative way of providing information on advances in medicine and new therapeutic areas. Physicians continue to rely on journal articles as a key source of new scientific and medical information. We offer a full range of reprint/ePrint services to aid your promotional efforts, from black and white to multiple pages in full colour, a single article or collection from within a range of our journals and evidence-based medicine products.

### Reprints are an ideal way to:

- Support new product launches and product development
- Update target audiences with important developments in medicine
- Endorse your product to a wider audience
- Distribute to conference delegates and visitors at exhibitions
- Gain maximum exposure and recognition

### All reprints are:

- Customizable with covers, company logos and legal disclaimers
- Easily distributable to your key contacts and prospects
- Trusted by researchers, scientists and clinicians throughout the world
- Translatable into all languages

Please contact Joanne Walker at [j.walker@future-science-group.com](mailto:j.walker@future-science-group.com) to secure your competitively priced reprint/ePrint solution today.



Unique coverage from bench to bedside of the latest developments in healthcare and biomedical research.

**Access to electronic content is via:**

- [www.expert-reviews.com](http://www.expert-reviews.com)
- [www.futuremedicine.com](http://www.futuremedicine.com)
- [www.future-science.com](http://www.future-science.com)

**Electronic licenses and collections**

Future Science Group electronic licenses include a selection of journals, eBooks or entire collections – providing the user with perpetual coverage of the latest developments in healthcare and biomedical research.

**Journal collections**

Our 'selected' journal collections grouped by subject field are available at special discounted prices for institutions, libraries and consortia. Customized packages are also available to suit your organizations requirements.

**eBook collections**

Future Science Group eBooks are offered for one-off purchase as an annual package, or via a subscription model. Libraries and organizations can either purchase the entire annual collection or any number of subject collections.

**Library Administration Area**

Benefit from your own specifically enhanced access interface. Benefits include:

- Desktop access 24/7
- Rapid publication
- Special Focus Issues
- Web feeds (RSS)
- Table of Content e-alerts
- MARC records for eBooks
- Searchable online archives
- Reference linking within and beyond Future Science Group
- Content listed on CrossRef Search

**Services for site license customers**

- Flexible purchasing
- Accessible for all institution types
- COUNTER compliant usage reports
- ATHENS & Shibboleth authentication compliance
- Reliable publishing platform
- Dynamic customer services
- Promotion tools upon request

# Information for librarians



## How site license pricing is calculated

Pricing is calculated using institution type:

- Academic/Hospitals – prices are independent of institutional size
- Corporate, Government – bands based on Research and Development staff figure and no. of research sites
- Consortia, multi-site and global organizations – please contact your local sales representative

**Consortia** – Future Science Group works with consortia of various types and sizes and welcomes discussion with all consortium managers. COUNTER-compliant usage statistics are provided for each institution. The benefits for the consortium include discounts on list price. Members have the flexibility to select the publications they want to include, or Future Science Group will work with the consortium to create customized packages.

**Institutional subscriptions** – Future Science Group operates a pricing model in which the type and size of the subscribing institution determines the subscription rate.

**Personal subscriptions** – available to all Future Science Group journals or individual eBooks.

**Free trials** – institutions can trial site license access to any publication to evaluate content and online functionality. Free trials provide online access via IP authentication and usage statistics will be provided. To request a free trial, please contact Annabelle Fairest at [a.fairest@future-science-group.com](mailto:a.fairest@future-science-group.com)

**eTOC RSS feeds** – receive news of the latest research straight to your desktop with our FREE electronic table of contents alerts (eTOC) and RSS feeds.

**Indexing** – Future Science Group titles are abstracted and indexed in all the main databases including MEDLINE/Index Medicus, EMBASE/Excerpta Medica.

## Ordering Information

For further details or to request a quote contact:

[sales@future-science-group.com](mailto:sales@future-science-group.com)



# Information for authors

Future Science Group titles publish a range of article types, including reviews, perspectives and original research articles. Unsolicited contributions to all Future Science Group journals are actively encouraged. A full explanation of our editorial policies and author options is available at the website for each of the Future Science Group imprints. Please see [www.expert-reviews.com](http://www.expert-reviews.com), [www.futuremedicine.com](http://www.futuremedicine.com) or [www.future-science.com](http://www.future-science.com) for full details.

Future Science Group titles endorse the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for Medical Journal Editors, and Code of Conduct for Editors of Biomedical Journals, produced by the Committee on Publication Ethics. Our full Editorial Policy can be found in the Author Guidelines. All journals operate a full author disclosure and conflict of interest policy.

## Why publish with the Future Science Group?

- We welcome the submission of unsolicited articles or article proposals
- Exemplary editorial and publication support provided
- Fast-track publication as standard – all articles are published online within 12 weeks of first draft submission. Accelerated publication options are also available (fee based), with a submission to online publication timeline of within 6 weeks pending successful peer review.
- No page charges
- Indexing in major databases
- Award-winning standards of journal presentation
- High-quality platform of both clinical research data and reviews
- Trusted, ethical publication standards
- Global distribution of all journals

Receipt of all manuscripts will be acknowledged within 2 working days and authors will be notified as to whether the article is to progress to external review.

If you have any queries about submitting a manuscript to any Future Science Group title or participating in our eBook program, please contact Laura Dormer (Senior Manager) at [l.dormer@future-science-group.com](mailto:l.dormer@future-science-group.com). For new article proposals, please provide a very brief article outline and working title in the first instance.



GET IN  
THE zone!

# Bioanalysiszone

The face of the bioanalysis community

Register now for exclusive access!

- » Access to content
- » Free articles from *Bioanalysis*
- » Connect and interact with your peers using our focused forum

[www.bioanalysis-zone.com](http://www.bioanalysis-zone.com)

# Contacts

## UK, USA, Europe, Rest of World

### Future Science Group

Unitec House  
2 Albert Place  
London  
N3 1QB, UK

T: **+44 (0)20 8371 6080**  
F: **+44 (0)20 8371 6099**  
E: **info@futuremedicine.com**

For customers in North America:  
**sales.us@futuremedicine.com**

## China

### Charlesworth China

Floor 12, Xiandai Baili Dasha  
(Beijing Modern Palace Building)  
No.20 Dongsanhuan Nanlu  
Daluyuan, Chaoyang District  
Beijing 100022, China

T: **+86 (0)10 6779 1601**  
F: **+86 (0)10 6779 9806**  
E: **sales@charlesworth.com.cn**

## Republic of Korea

### Shinwon Datonet Inc.

200-20, Dongkyo-Dong  
Mapo-Gu  
Seoul 121-819  
Korea

T: **+822 326 3535**  
F: **+822 326 0219**  
E: **info@shinwon.co.kr**

## Japan

### Technomics, Inc.

Ohku Building Kyobashi  
1-16-10 Kyobashi  
Chuoku, Tokyo 104-0031  
Japan

T: **+81 (0)3 3538 2531**  
F: **+81 (0)3 3538 2537**  
E: **sales@technomics.co.jp**

## Far East (excluding Korea, China and Japan)

### Roslinda M Razi

MY Mailbox 882251  
Singapore  
919191

T: **+65 8113 5406**  
E: **r.razi@futuremedicine.com**

### iGroup Asia Pacific

Unit 2003A, 20/F  
Causeway Bay Plaza I  
489 Hennessy Road  
Causeway Bay, Hong Kong

T: **+852 2572 7228**  
F: **+852 2575 8822**  
E: **info.hk@igroupnet.com**

## India

### Informatics (I) Limited

194, R V Road, Basvanagudi  
Bangalore - 560 004  
India

T: **+91 80 4038 7777**  
F: **+91 80 4038 7600**  
E: **info@informindia.co.in**  
**www.informindia.co.in**

## Middle East

### Arabian Advanced Systems

PO Box 20129  
Riyadh 11455  
Saudi Arabia

T: **+966 1 477 0477**  
F: **+966 1 478 3512**  
E: **info@aas.com.sa**

## Latin America and the Caribbean

### dotLib

Av. das Americas  
3434 - Bloco 2 - Sala 506  
Rio de Janeiro  
RJ 22640-102  
Brazil

T: **+55 (21) 3431 3430**  
F: **+55 (21) 3431 3480**  
E: **info@dotlib.com**

## Southern Africa

### WorldWide Information Services

Private Bag X10072  
RANDBURG 2125  
South Africa

T: **+27 11 789 9947**  
F: **+27 11 789 9967**  
E: **info@wwis.co.za**